Reaction

Renal Mass reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,035 reports · 41 co-occurring drugs

As of the last recalculation, Renal Mass appears in 2,035 FAERS reports alongside 41 co-occurring drug terms. The strongest observed disproportionality signal is ANAKINRA (PRR 16.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Anakinra	27	16.9	16.9
Basiliximab	16	14.0	14.0
Octreotide Acetate	40	13.6	13.6
Instalax Polyethylene Glycol 3350	13	10.8	10.8
Polyethylene Glycol 400	13	10.5	10.6
Cholestyramine	11	9.3	9.4
Indapamide	16	9.2	9.2
Chlorthalidone	10	8.8	8.9
Dexlansoprazole	35	8.7	8.7
Gemfibrozil	12	8.1	8.1
Lansoprazole	129	7.8	7.8
Medroxyprogesterone Acetate	36	7.5	7.5
Tiotropium Bromide Inhalation Spray	8	7.3	7.3
Sulfasalazine	54	7.2	7.2
Everolimus	35	7.1	7.1
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	6	6.8	6.8
Pazopanib Hydrochloride	17	6.5	6.5
Emtricitabine And Tenofovir Alafenamide	7	6.3	6.3
Sunitinib Malate	23	6.0	6.0
Sitagliptin	39	5.6	5.6
Polatuzumab Vedotin	5	5.3	5.3
Lanreotide Acetate	4	5.2	5.2
Asfotase Alfa	5	5.1	5.1
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	9	5.1	5.1
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide	5	5.1	5.1
Ibrutinib	37	4.8	4.8
Axitinib	9	4.7	4.7
Niraparib	10	4.6	4.6
Avapritinib	5	4.2	4.2
Emtricitabine And Tenofovir Disoproxil Fumarate	18	4.1	4.1
Tenofovir Disoproxil Fumarate	13	4.0	4.0
Dofetilide	4	3.9	3.9
Ranitidine Hydrochloride	20	3.8	3.8
Ravulizumab	5	3.8	3.8
Liraglutide	17	3.5	3.5
Diroximel Fumarate	4	3.4	3.4
Acalabrutinib	4	3.4	3.4
Cabozantinib	15	3.2	3.2
Olaparib	6	2.9	2.9
Exenatide	15	2.9	2.9
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	7	2.3	2.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.